STEMCELL Technologies is a leader in the development of specialty cell culture media, cell separation products and accessory reagents for life science research. Driven by science and a passion for quality, STEMCELL delivers over 1500 products to more than 70 countries worldwide. To learn more, visit https://www.stemcell.com
Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development. It is backed by £38m of funding from GlaxoSmithKline, the Wellcome Trust and the UK Government. Consisting of an incubator, an accelerator and a hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to London and Cambridge.
Since 1999, Stratagem has partnered with innovative businesses to help them realise the full value of their intellectual property. Originally founded to support the biotechnology sector, we now work internationally across life sciences, pharmaceuticals, chemistry, engineering and technology - advising clients from ambitious start-ups to scaling SMEs and global corporates.
Our attorneys combine sector-specific knowledge with legal and commercial expertise to deliver tailored IP strategies that align with long-term business goals. Whether a business is preparing for funding, launching a product, or entering new markets, we act as an extension of their team - cutting through complexity and focusing on what matters most: protecting and leveraging their IP for growth.
With offices in Cambridge and Bristol and attorneys based throughout the UK, we support clients with patents, trade marks, IP strategy, due diligence, investor-ready audits, contracts and licensing - both in the UK and internationally.
To contact us please email: [email protected] or via our website https://www.stratagemipm.co.uk Enquiries are directed to the most relevant attorney based on technology and sector. We offer a free 30-minute consultation to explore the company’s goals, answer their IP questions, and recommend next steps.
Our attorneys combine sector-specific knowledge with legal and commercial expertise to deliver tailored IP strategies that align with long-term business goals. Whether a business is preparing for funding, launching a product, or entering new markets, we act as an extension of their team - cutting through complexity and focusing on what matters most: protecting and leveraging their IP for growth.
With offices in Cambridge and Bristol and attorneys based throughout the UK, we support clients with patents, trade marks, IP strategy, due diligence, investor-ready audits, contracts and licensing - both in the UK and internationally.
To contact us please email: [email protected] or via our website https://www.stratagemipm.co.uk Enquiries are directed to the most relevant attorney based on technology and sector. We offer a free 30-minute consultation to explore the company’s goals, answer their IP questions, and recommend next steps.
No data available
Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading independent provider of integrated drug discovery and pre-clinical resource and expertise. We undertake target validation, hit identification, hit-to-lead and lead optimisation projects and complete drug discovery programs. We offer fully integrated discovery project support, as well as discipline specific support in chemistry, computational sciences, in vitro biology, DMPK or in vivo pharmacology as needed by our collaborating clients. Sygnature adds significant value to collaborations by providing advanced scientific knowledge and intellectual input to accelerate clients’ drug discovery projects from target validation and lead optimisation through to pre-clinical candidate. Since 2011, 31 compounds discovered by Sygnature for clients have entered pre-clinical development and so far, 15 of these have progressed to clinical trials (Phases I, II and III). A multi award-winning company, Sygnature operates fully enabled research facilities in Nottingham and Alderley Park, UK, housing the most technologically advanced laboratories and teams of expert scientists (>80% with PhDs). For additional information, go to: https://www.sygnaturediscovery.com
Tailor Bio is a techbio startup developing targeted therapies for cancers with Chromosomal Instability (CIN). CIN is a genomic phenomenon present in 80% of all cancers which leads to aggressive, difficult to treat cancers. Using an AI-driven platform for pan-cancer precision medicine, Tailor aims to make precision medicine a reality for some of the deadliest cancers with CIN.
CK Clinical is part of a family of science-based consultancies – The CK Group. We provide Functional Service Outsourcing services as well as helping to recruit for contract and permanent job opportunities across the UK and Europe. We aim to provide resource solutions that are tailored and cost effective to organisations ranging from small start ups to large international pharmaceutical companies. We have a track record delivering Functional Service outsourcing and contingency recruitment solutions to some of the most innovative new Biotechs right the way through to helping 9 of the top 10 major Pharma companies.
A stem cell drug discovery company
Taylor Wessing LLP has offices in London and Cambridge and is a leading international law firm with 22 offices in Europe, the Middle East and Asia. We advise life science businesses, those who fund them and those who work for them. Our extensive Life Sciences Group combines lawyers from Taylor Wessing’s intellectual property, corporate, competition, dispute resolution and employment practices. The Group in the UK includes 15 lawyers with first degrees in life sciences subjects, of whom several have PhDs and many have spent periods working in the biotech and pharmaceutical industry.
MedTech in stealth developing frozen cell sampling technologies